Skip to content

EBITDA at other companies

Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$43.68M-16.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$90.3M-49.2%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$139.22M-26.0%
Eli Lilly logo
Eli LillyLLY
Amgen logo
AmgenAMGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

$27.3Mebit+
$64.0KDepreciation Depletion & Amortization
=-$27.2M

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s EBITDA?
MBX Biosciences, Inc. (MBX) reported EBITDA of -$27.2M in Q1 2026.
How has MBX Biosciences, Inc.'s EBITDA changed year-over-year?
MBX Biosciences, Inc.'s EBITDA decreased by 2.8% year-over-year, from -$26.45M to -$27.2M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.